U.S. Faces Potential $189 Billion Loss in Healthcare Savings Due to Biosimilar Void
A recent industry report highlights the risk of an impending biosimilar void, which could cost the U.S. healthcare system up to $189 billion over the next decade. The issue arises because no off-patent versions are currently being developed for 90% of brand-name biologics that will lose market exclusivity in this period. This lack of biosimilar development threatens significant savings opportunities, as these lower-cost alternatives typically enter the market after patent expiration to provide competition and reduce drug prices. The report underscores a critical gap between the expected loss of exclusivity for major biologic drugs and the absence of corresponding biosimilars being developed.
